GBM ranks high on the cancer spectrum owing to epigenetic-based prognostic markers, e.g., isocitrate dehydrogenase 1 (IDH1) gene mutations with high global DNA methylation levels and hypermethylation in the O6-methylguanine DNA methyltransferase (MGMT) gene promoter region, which play a pivotal role in the making of clinical decisions. Here, MGMT is linked to glioblastoma.